Does CRIZOTINIB Cause Second primary malignancy? 68 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 68 reports of Second primary malignancy have been filed in association with CRIZOTINIB (Xalkori). This represents 0.7% of all adverse event reports for CRIZOTINIB.
68
Reports of Second primary malignancy with CRIZOTINIB
0.7%
of all CRIZOTINIB reports
9
Deaths
13
Hospitalizations
How Dangerous Is Second primary malignancy From CRIZOTINIB?
Of the 68 reports, 9 (13.2%) resulted in death, 13 (19.1%) required hospitalization, and 2 (2.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CRIZOTINIB. However, 68 reports have been filed with the FAERS database.
What Other Side Effects Does CRIZOTINIB Cause?
Death (2,028)
Neoplasm progression (1,161)
Nausea (820)
Disease progression (677)
Diarrhoea (631)
Vomiting (600)
Fatigue (419)
Off label use (353)
Dyspnoea (352)
Visual impairment (315)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which CRIZOTINIB Alternatives Have Lower Second primary malignancy Risk?
CRIZOTINIB vs CROFELEMER
CRIZOTINIB vs CROMOLYN
CRIZOTINIB vs CROTALIDAE POLYVALENT IMMUNE FAB
CRIZOTINIB vs CUBICIN
CRIZOTINIB vs CUPRIC